Trial Profile
A Multi-center, Randomized, Double-blined, Placebo Parallel Controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Mortality of Subjects With Chronic Systolic Heart Failure on Standard HF Therapy.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Recombinant human neuregulin 1-beta (Primary)
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Sponsors Zensun (Shanghai) Sci & Tech
- 30 Jan 2024 Planned End Date changed from 1 Feb 2023 to 1 Feb 2026.
- 30 Jan 2024 Planned primary completion date changed from 1 Feb 2022 to 1 Feb 2026.
- 22 Jun 2018 Status changed from not yet recruiting to recruiting.